---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-040194"
form_type: "8-K/A"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T10:58:05.898361+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma regains Nasdaq compliance after equity shortfall notice

## Summary
- On April 30, 2025, Nasdaq notified ABVC that stockholders' equity of $723,959 as of April 23 failed Listing Rule 5550(b)(1).
- On May 5, 2025, Nasdaq confirmed compliance after ABVC's Q1 2025 10-Q showed equity of $7,956,295, closing the matter.
- The company avoided delisting by demonstrating equity above the required minimum through its quarterly filing.

## SEC filing metadata
- accession: 0001213900-25-040194
- form_type: 8-K/A
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390025040194/0001213900-25-040194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390025040194/ea0240961-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-040194
- JSON: https://secwatch.observer/filing/0001213900-25-040194.json
- Plain text: https://secwatch.observer/filing/0001213900-25-040194.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.